72 results
6-K
EX-99.5
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
deductible from future taxable profits
Other deferred taxes representing assets
Investment deduction
Deduction for innovation income
Excess depreciations
DBI
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
regarding the timing and likelihood of business development projects and external innovation, statements regarding the amount and timing of potential future … -changing science and innovation for more years of life and quality of life. Our Mission We accelerate transformational innovation through the relentless
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
science and innovation to deliver more years of life and quality of life. We are committed to improving patients’ lives worldwide by targeting … and oncology with the aim to transform patient outcomes through life-changing science and innovation. Galapagos is at a pivotal juncture resetting its
6-K
EX-99.1
GLPG
Galapagos NV
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
and accelerating innovation to address important medical needs.”
About Galapagos
We are a biotechnology company with operations in Europe and the US
6-K
EX-99.1
olje7tavrvbo3g
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.1
8bigzs2i dqzx3fj0msx
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
hhfgc2cgrddlh6ra
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
ykgkmxly
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
4bm27c
20 Sep 23
Galapagos appoints Simon Sturge to its Board of Directors
6:00am
6-K
EX-99.1
b1sxqor88hlx
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
EX-99.2
oxwhq0ansy55 v0
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
zos0r9
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
8360rszq
15 Jun 23
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
5:03pm
6-K
EX-99.1
k6g7n12bkdwbgj3pq
13 Jun 23
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
7:53am
6-K
EX-99.1
s2tnq xfaiml
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
vppy1jc9 sn
25 May 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
5:49pm
6-K
EX-99.1
z6iika0ds7 gi
23 May 23
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
7:30am
6-K
EX-99.1
su9mg6jefjd3ztq0ty
31 Mar 23
Current report (foreign)
6:05am
6-K
EX-99.1
wacce45a1n8e qm
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am